Dosing & Uses
COVID-19 (EUA submitted)
October 9, 2021: Request for emergency use authorization (EUA) initiated for nonhospitalized patients with COVID-19 at risk of clinical progression to severe disease
Next:
Pharmacology
Mechanism of Action
Non-competing SARS-CoV-2 monoclonal neutralizing antibodies derived from convalesced COVID-19 patients
The antibodies have nonoverlapping epitope binding regions
Previous
Next:
Images
No images available for this drug.
Previous
Next:
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.
